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The bacterial phosphotriesterase (PTE), originally purified from the bacterium Pseudomonas diminuta, catalyzes 
the hydrolysis of the organophosphate insecticide paraoxon at a rate near the diffusion-controlled limit.  The 
protein has been crystallized and the three-dimensional structure determined to high resolution.  The protein 
adopts a (β/α)8-barrel structural fold and the active site is dominated by a binuclear metal center with a bridging 
hydroxide that is used for direct nucleophilic attack on the phosphorus center of the substrate.  The wild-type 
enzyme is stereoselective for the hydrolysis of chiral organophosphate substrates.  For example, the wild-type 
enzyme preferentially hydrolyzes the SP-enantiomer of methyl phenyl p-nitrophenyl phosphate by a factor of 
93:1.  The mutation of Gly-60 to alanine (G60A) enhances the preference for hydrolysis of the SP-enantiomer to 
a factor of 13,000:1 by reducing the rate of hydrolysis of the RP-enantiomer.  The stereoselectivity of PTE can 
be reversed by mutation of three residues within the active site (I106G/F132G/H257Y) and now the RP-
enantiomer is preferentially hydrolyzed by a factor of 118:1.  Therefore, the stereoselectivity can be changed by 
more than four orders-of-magnitude by mutation of only four amino acids changes in the active site and thus 
PTE variants can be used to resolve racemic mixtures of chiral organophosphate esters.  PTE was 
demonstrated to catalyze the hydrolysis of the organophosphate nerve agents tabun (GA), sarin (GB), soman 
(GD), cyclosarin (GF), VX, and VR.  Screening of a small library of active site mutants identified one mutant 
(H257Y/L303T) that was particularly efficient toward the hydrolysis of the G-agents (in collaboration with Dr. 
Steve Harvey).  The YT mutant of PTE hydrolyzed GB with a kcat of 3.1 x 104 min-1.  This mutant, at a dose of 1 
mg/Kg, was shown to significantly protect guinea pigs from exposure to sarin. The LD50 increased by more than 
a factor of 65 (in collaboration with Dr. Douglas Cerasoli).  Coating of the surface of the YT variant with a thin 
ultrahydrophilic semipermeable poly(carboxybetaine) polymer enhanced protein stability, reduced 
immunological complications and protected rodents from repeated exposures to sarin over a period of 1-week 
(in collaboration with Dr. Shaoyi Jiang).  From a 30,000 member mutant library, multiple variants were identified 
for the catalytic hydrolysis of VX and VR.  The best mutants identified to date for the hydrolysis of (SP)-VX and 
(SP)-VR were enhanced more than 10,000-fold, relative to the wild-type PTE (in collaboration with Dr. S. 
Harvey).  These results demonstrate that the active site of PTE can be readily manipulated to engineer protein 
variants with enhanced catalytic properties for hydrolysis of highly toxic organophosphate nerve agents.                            
 
 
 
